Difference between revisions of "Lung carcinoma with EGFR mutation"

From Libre Pathology
Jump to navigation Jump to search
 
(10 intermediate revisions by the same user not shown)
Line 1: Line 1:
'''Lung adenocarcinoma with EGFR rearrangement''' is a molecular subtype of [[lung adenocarcinoma]].
'''Lung carcinoma with EGFR mutation''' is a molecular subtype of [[lung carcinoma]]. Morphologically, these tumours are typically [[adenocarcinoma]]s.
 
==General==
*Testing indicated in [[non-small cell carcinoma]], [[adenosquamous carcinoma of the lung]], as well as [[lung adenocarcinoma]].
**Testing done together with ALK.
*EGRF mutation excludes [[Lung carcinoma with ALK rearrangement|ALK rearrangement]].<ref name=pmid23729361>{{Cite journal  | last1 = Gainor | first1 = JF. | last2 = Varghese | first2 = AM. | last3 = Ou | first3 = SH. | last4 = Kabraji | first4 = S. | last5 = Awad | first5 = MM. | last6 = Katayama | first6 = R. | last7 = Pawlak | first7 = A. | last8 = Mino-Kenudson | first8 = M. | last9 = Yeap | first9 = BY. | title = ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. | journal = Clin Cancer Res | volume = 19 | issue = 15 | pages = 4273-81 | month = Aug | year = 2013 | doi = 10.1158/1078-0432.CCR-13-0318 | PMID = 23729361 }}</ref>
 
Treatement:<ref name=pmid20887192>{{Cite journal  | last1 = da Cunha Santos | first1 = G. | last2 = Shepherd | first2 = FA. | last3 = Tsao | first3 = MS. | title = EGFR mutations and lung cancer. | journal = Annu Rev Pathol | volume = 6 | issue =  | pages = 49-69 | month =  | year = 2011 | doi = 10.1146/annurev-pathol-011110-130206 | PMID = 20887192 }}</ref>
*[[Tyrosine kinase inhibitors]].
 
===Associations===
Varies significantly by population:<ref name=pmid27738317>{{Cite journal  | last1 = Zhang | first1 = YL. | last2 = Yuan | first2 = JQ. | last3 = Wang | first3 = KF. | last4 = Fu | first4 = XH. | last5 = Han | first5 = XR. | last6 = Threapleton | first6 = D. | last7 = Yang | first7 = ZY. | last8 = Mao | first8 = C. | last9 = Tang | first9 = JL. | title = The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. | journal = Oncotarget | volume = 7 | issue = 48 | pages = 78985-78993 | month = Nov | year = 2016 | doi = 10.18632/oncotarget.12587 | PMID = 27738317 }}</ref>
{| class="wikitable sortable"
! Population
! Prevalence
! Category
|-
| Europe
| 14%
| Geographic
|-
| China
| 38%
| Geographic
|-
| Females
| 44%
| Patient characteristics
|-
| Males
| 24%
| Patient characteristics
|-
| Non-smokers
| 49%
| Patient characteristics
|-
| Smokers or past smokers
| 22%
| Patient characteristics
|-
| Adenocarcinoma
| 38%
| Pathology
|-
| Non-adenocarcinoma
| 12%
| Pathology
|}


==Sign out==
==Sign out==
Line 9: Line 57:
==See also==
==See also==
*[[Lung carcinoma with ALK rearrangement]].
*[[Lung carcinoma with ALK rearrangement]].
*[[Epidermal growth factor receptor inhibitors]].
*[[ROS1-rearranged non-small cell lung carcinoma]].


==References==
==References==

Latest revision as of 02:19, 31 December 2019

Lung carcinoma with EGFR mutation is a molecular subtype of lung carcinoma. Morphologically, these tumours are typically adenocarcinomas.

General

Treatement:[2]

Associations

Varies significantly by population:[3]

Population Prevalence Category
Europe 14% Geographic
China 38% Geographic
Females 44% Patient characteristics
Males 24% Patient characteristics
Non-smokers 49% Patient characteristics
Smokers or past smokers 22% Patient characteristics
Adenocarcinoma 38% Pathology
Non-adenocarcinoma 12% Pathology

Sign out

Lung core biopsy, left lower lobe:
	- EGFR mutation POSITIVE, ALK rearrangement NEGATIVE

See also

References

  1. ↑ Gainor, JF.; Varghese, AM.; Ou, SH.; Kabraji, S.; Awad, MM.; Katayama, R.; Pawlak, A.; Mino-Kenudson, M. et al. (Aug 2013). "ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.". Clin Cancer Res 19 (15): 4273-81. doi:10.1158/1078-0432.CCR-13-0318. PMID 23729361.
  2. ↑ da Cunha Santos, G.; Shepherd, FA.; Tsao, MS. (2011). "EGFR mutations and lung cancer.". Annu Rev Pathol 6: 49-69. doi:10.1146/annurev-pathol-011110-130206. PMID 20887192.
  3. ↑ Zhang, YL.; Yuan, JQ.; Wang, KF.; Fu, XH.; Han, XR.; Threapleton, D.; Yang, ZY.; Mao, C. et al. (Nov 2016). "The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis.". Oncotarget 7 (48): 78985-78993. doi:10.18632/oncotarget.12587. PMID 27738317.
Retrieved from "https://librepathology.org/w/index.php?title=Lung_carcinoma_with_EGFR_mutation&oldid=50595"